302 related articles for article (PubMed ID: 26787654)
1. Multigene testing of moderate-risk genes: be mindful of the missense.
Young EL; Feng BJ; Stark AW; Damiola F; Durand G; Forey N; Francy TC; Gammon A; Kohlmann WK; Kaphingst KA; McKay-Chopin S; Nguyen-Dumont T; Oliver J; Paquette AM; Pertesi M; Robinot N; Rosenthal JS; Vallee M; Voegele C; Hopper JL; Southey MC; Andrulis IL; John EM; Hashibe M; Gertz J; ; Le Calvez-Kelm F; Lesueur F; Goldgar DE; Tavtigian SV
J Med Genet; 2016 Jun; 53(6):366-76. PubMed ID: 26787654
[TBL] [Abstract][Full Text] [Related]
2. Rare, evolutionarily unlikely missense substitutions in CHEK2 contribute to breast cancer susceptibility: results from a breast cancer family registry case-control mutation-screening study.
Le Calvez-Kelm F; Lesueur F; Damiola F; Vallée M; Voegele C; Babikyan D; Durand G; Forey N; McKay-Chopin S; Robinot N; Nguyen-Dumont T; Thomas A; Byrnes GB; ; Hopper JL; Southey MC; Andrulis IL; John EM; Tavtigian SV
Breast Cancer Res; 2011 Jan; 13(1):R6. PubMed ID: 21244692
[TBL] [Abstract][Full Text] [Related]
3. Classification of rare missense substitutions, using risk surfaces, with genetic- and molecular-epidemiology applications.
Tavtigian SV; Byrnes GB; Goldgar DE; Thomas A
Hum Mutat; 2008 Nov; 29(11):1342-54. PubMed ID: 18951461
[TBL] [Abstract][Full Text] [Related]
4. RAD51 and breast cancer susceptibility: no evidence for rare variant association in the Breast Cancer Family Registry study.
Le Calvez-Kelm F; Oliver J; Damiola F; Forey N; Robinot N; Durand G; Voegele C; Vallée MP; Byrnes G; Registry BC; Hopper JL; Southey MC; Andrulis IL; John EM; Tavtigian SV; Lesueur F
PLoS One; 2012; 7(12):e52374. PubMed ID: 23300655
[TBL] [Abstract][Full Text] [Related]
5. The BARD1 Cys557Ser variant and breast cancer risk in Iceland.
Stacey SN; Sulem P; Johannsson OT; Helgason A; Gudmundsson J; Kostic JP; Kristjansson K; Jonsdottir T; Sigurdsson H; Hrafnkelsson J; Johannsson J; Sveinsson T; Myrdal G; Grimsson HN; Bergthorsson JT; Amundadottir LT; Gulcher JR; Thorsteinsdottir U; Kong A; Stefansson K
PLoS Med; 2006 Jul; 3(7):e217. PubMed ID: 16768547
[TBL] [Abstract][Full Text] [Related]
6. Breast cancer risks associated with missense variants in breast cancer susceptibility genes.
Dorling L; Carvalho S; Allen J; Parsons MT; Fortuno C; González-Neira A; Heijl SM; Adank MA; Ahearn TU; Andrulis IL; Auvinen P; Becher H; Beckmann MW; Behrens S; Bermisheva M; Bogdanova NV; Bojesen SE; Bolla MK; Bremer M; Briceno I; Camp NJ; Campbell A; Castelao JE; Chang-Claude J; Chanock SJ; Chenevix-Trench G; ; Collée JM; Czene K; Dennis J; Dörk T; Eriksson M; Evans DG; Fasching PA; Figueroa J; Flyger H; Gabrielson M; Gago-Dominguez M; García-Closas M; Giles GG; Glendon G; Guénel P; Gündert M; Hadjisavvas A; Hahnen E; Hall P; Hamann U; Harkness EF; Hartman M; Hogervorst FBL; Hollestelle A; Hoppe R; Howell A; ; ; Jakubowska A; Jung A; Khusnutdinova E; Kim SW; Ko YD; Kristensen VN; Lakeman IMM; Li J; Lindblom A; Loizidou MA; Lophatananon A; Lubiński J; Luccarini C; Madsen MJ; Mannermaa A; Manoochehri M; Margolin S; Mavroudis D; Milne RL; Mohd Taib NA; Muir K; Nevanlinna H; Newman WG; Oosterwijk JC; Park SK; Peterlongo P; Radice P; Saloustros E; Sawyer EJ; Schmutzler RK; Shah M; Sim X; Southey MC; Surowy H; Suvanto M; Tomlinson I; Torres D; Truong T; van Asperen CJ; Waltes R; Wang Q; Yang XR; Pharoah PDP; Schmidt MK; Benitez J; Vroling B; Dunning AM; Teo SH; Kvist A; de la Hoya M; Devilee P; Spurdle AB; Vreeswijk MPG; Easton DF
Genome Med; 2022 May; 14(1):51. PubMed ID: 35585550
[TBL] [Abstract][Full Text] [Related]
7. Effect of CHEK2 missense variant I157T on the risk of breast cancer in carriers of other CHEK2 or BRCA1 mutations.
Cybulski C; Górski B; Huzarski T; Byrski T; Gronwald J; Debniak T; Wokolorczyk D; Jakubowska A; Serrano-Fernández P; Dork T; Narod SA; Lubinski J
J Med Genet; 2009 Feb; 46(2):132-5. PubMed ID: 18930998
[TBL] [Abstract][Full Text] [Related]
8. [The clinical importance of a genetic analysis of moderate-risk cancer susceptibility genes in breast and other cancer patients from the Czech Republic].
Pohlreich P; Kleibl Z; Kleiblová P; Janatová M; Soukupová J; Macháčková E; Házová J; Vašíčková P; Sťahlová Hrabincová E; Navrátilová M; Svoboda M; Foretová L
Klin Onkol; 2012; 25 Suppl():S59-66. PubMed ID: 22920209
[TBL] [Abstract][Full Text] [Related]
9. Clinical Management of Patients at Risk for Hereditary Breast Cancer with Variants of Uncertain Significance in the Era of Multigene Panel Testing.
Chang J; Seng S; Yoo J; Equivel P; Lum SS
Ann Surg Oncol; 2019 Oct; 26(10):3389-3396. PubMed ID: 31342386
[TBL] [Abstract][Full Text] [Related]
10. BARD1 variants Cys557Ser and Val507Met in breast cancer predisposition.
Vahteristo P; Syrjäkoski K; Heikkinen T; Eerola H; Aittomäki K; von Smitten K; Holli K; Blomqvist C; Kallioniemi OP; Nevanlinna H
Eur J Hum Genet; 2006 Feb; 14(2):167-72. PubMed ID: 16333312
[TBL] [Abstract][Full Text] [Related]
11. Functional Analysis of Missense Variants in the Putative Breast Cancer Susceptibility Gene XRCC2.
Hilbers FS; Luijsterburg MS; Wiegant WW; Meijers CM; Völker-Albert M; Boonen RA; van Asperen CJ; Devilee P; van Attikum H
Hum Mutat; 2016 Sep; 37(9):914-25. PubMed ID: 27233470
[TBL] [Abstract][Full Text] [Related]
12. The spectrum of ATM missense variants and their contribution to contralateral breast cancer.
Broeks A; Braaf LM; Huseinovic A; Schmidt MK; Russell NS; van Leeuwen FE; Hogervorst FB; Van 't Veer LJ
Breast Cancer Res Treat; 2008 Jan; 107(2):243-8. PubMed ID: 17393301
[TBL] [Abstract][Full Text] [Related]
13. [Association between single nucleotide polymorphisms of BARD 1 gene and susceptibility of early-onset breast cancer in Uygur women in Xinjiang].
Sun G; Wang JT; Ma BL; Geng ZL; Ren GH; Shan MH; Ma B; Ma LL; Wang Y
Zhonghua Zhong Liu Za Zhi; 2012 May; 34(5):341-7. PubMed ID: 22883453
[TBL] [Abstract][Full Text] [Related]
14. Germline CHEK2 mutations in Jewish Ashkenazi women at high risk for breast cancer.
Laitman Y; Kaufman B; Lahad EL; Papa MZ; Friedman E
Isr Med Assoc J; 2007 Nov; 9(11):791-6. PubMed ID: 18085035
[TBL] [Abstract][Full Text] [Related]
15. Candidate gene analysis of BRCA1/2 mutation-negative high-risk Russian breast cancer patients.
Sokolenko AP; Preobrazhenskaya EV; Aleksakhina SN; Iyevleva AG; Mitiushkina NV; Zaitseva OA; Yatsuk OS; Tiurin VI; Strelkova TN; Togo AV; Imyanitov EN
Cancer Lett; 2015 Apr; 359(2):259-61. PubMed ID: 25619955
[TBL] [Abstract][Full Text] [Related]
16. Common variation in BRCA2 and breast cancer risk: a haplotype-based analysis in the Multiethnic Cohort.
Freedman ML; Penney KL; Stram DO; Le Marchand L; Hirschhorn JN; Kolonel LN; Altshuler D; Henderson BE; Haiman CA
Hum Mol Genet; 2004 Oct; 13(20):2431-41. PubMed ID: 15317758
[TBL] [Abstract][Full Text] [Related]
17. Clinical Actionability of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Risk Assessment.
Desmond A; Kurian AW; Gabree M; Mills MA; Anderson MJ; Kobayashi Y; Horick N; Yang S; Shannon KM; Tung N; Ford JM; Lincoln SE; Ellisen LW
JAMA Oncol; 2015 Oct; 1(7):943-51. PubMed ID: 26270727
[TBL] [Abstract][Full Text] [Related]
18. Multigene Panel Testing Detects Equal Rates of Pathogenic BRCA1/2 Mutations and has a Higher Diagnostic Yield Compared to Limited BRCA1/2 Analysis Alone in Patients at Risk for Hereditary Breast Cancer.
Kapoor NS; Curcio LD; Blakemore CA; Bremner AK; McFarland RE; West JG; Banks KC
Ann Surg Oncol; 2015 Oct; 22(10):3282-8. PubMed ID: 26219241
[TBL] [Abstract][Full Text] [Related]
19. A single nucleotide polymorphism in the 5' untranslated region of RAD51 and risk of cancer among BRCA1/2 mutation carriers.
Wang WW; Spurdle AB; Kolachana P; Bove B; Modan B; Ebbers SM; Suthers G; Tucker MA; Kaufman DJ; Doody MM; Tarone RE; Daly M; Levavi H; Pierce H; Chetrit A; Yechezkel GH; Chenevix-Trench G; Offit K; Godwin AK; Struewing JP
Cancer Epidemiol Biomarkers Prev; 2001 Sep; 10(9):955-60. PubMed ID: 11535547
[TBL] [Abstract][Full Text] [Related]
20. Comprehensive analysis of the ATM, CHEK2 and ERBB2 genes in relation to breast tumour characteristics and survival: a population-based case-control and follow-up study.
Einarsdóttir K; Rosenberg LU; Humphreys K; Bonnard C; Palmgren J; Li Y; Li Y; Chia KS; Liu ET; Hall P; Liu J; Wedrén S
Breast Cancer Res; 2006; 8(6):R67. PubMed ID: 17132159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
